News & Updates

Show Multimedia Only
Brigatinib a potential standard treatment alternative for treatment-naive ALK+ NSCLC

Brigatinib a potential standard treatment alternative for treatment-naive ALK+ NSCLC

30 Apr 2022 byAudrey Abella

In patients with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer (ALK+ NSCLC) who were ALK inhibitor-naïve, brigatinib showed superior efficacy and safety over crizotinib, according to the final results of the phase III ALTA-1L* trial presented at ELCC 2022.

30 Apr 2022